Short Interest in iSpecimen Inc. (NASDAQ:ISPC) Grows By 2,171.8%

iSpecimen Inc. (NASDAQ:ISPC) was the target of a large increase in short interest during the month of December. As of December 15th, there was short interest totaling 305,108 shares, an increase of 2,171.8% from the November 30th total of 13,430 shares. Approximately 3.6% of the company’s shares are sold short. Based on an average daily trading volume, of 364,222 shares, the short-interest ratio is currently 0.8 days. Based on an average daily trading volume, of 364,222 shares, the short-interest ratio is currently 0.8 days. Approximately 3.6% of the company’s shares are sold short.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of iSpecimen in a research report on Wednesday, October 8th. Wall Street Zen upgraded iSpecimen to a “sell” rating in a research note on Saturday, September 6th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has a consensus rating of “Sell”.

iSpecimen Price Performance

Shares of iSpecimen stock traded up $0.00 during trading on Thursday, hitting $0.39. The stock had a trading volume of 265,996 shares, compared to its average volume of 527,041. The business has a fifty day moving average of $0.58 and a two-hundred day moving average of $0.93. iSpecimen has a fifty-two week low of $0.36 and a fifty-two week high of $3.38. The firm has a market cap of $3.76 million, a P/E ratio of -0.05 and a beta of 1.80.

iSpecimen (NASDAQ:ISPC) last released its earnings results on Monday, November 17th. The company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($3.80) by $3.32. iSpecimen had a negative net margin of 343.86% and a negative return on equity of 531.78%. The business had revenue of $0.11 million for the quarter, compared to the consensus estimate of $3.33 million.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in iSpecimen stock. Scientech Research LLC purchased a new position in iSpecimen Inc. (NASDAQ:ISPC) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm purchased 29,488 shares of the company’s stock, valued at approximately $38,000. Scientech Research LLC owned about 0.30% of iSpecimen at the end of the most recent reporting period. Institutional investors own 13.62% of the company’s stock.

About iSpecimen

iSpecimen, Inc (NASDAQ:ISPC) operates an online life sciences marketplace designed to connect researchers with human biological specimens and associated clinical data. The company’s platform streamlines the sourcing of biospecimens—such as plasma, serum, fresh and frozen tissue, saliva, urine and peripheral blood mononuclear cells (PBMCs)—by matching demand from pharmaceutical, biotechnology, diagnostic and academic organizations with supply from a wide network of clinical sites and biobanks.

Through its on-demand procurement model, iSpecimen provides customized specimen collection and fulfillment services that help accelerate research timelines and improve data quality.